VIKAS KUNDRA to Neovascularization, Pathologic
This is a "connection" page, showing publications VIKAS KUNDRA has written about Neovascularization, Pathologic.
Connection Strength
0.514
-
REST promotes ETS1-dependent vascular growth in medulloblastoma. Mol Oncol. 2021 05; 15(5):1486-1506.
Score: 0.118
-
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.
Score: 0.080
-
Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
Score: 0.067
-
Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
Score: 0.057
-
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15.
Score: 0.047
-
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.
Score: 0.043
-
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006 Mar; 9(3):225-38.
Score: 0.042
-
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
Score: 0.030
-
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
Score: 0.019
-
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.
Score: 0.012